PatientsVille.com Logo

Metastases and Fluorouracil

PatientsVille

Metastases Symptoms and Causes

Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver.

Risk factors for primary liver cancer include

  • Having hepatitis B or C
  • Heavy alcohol use
  • Having cirrhosis, or scarring of the liver
  • Having hemochromatosis, an iron storage disease
  • Obesity and diabetes

Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation.

NIH: National Cancer Institute

Check out the latest treatments for metastases

metastases treatment research studies

Fluorouracil clinical trials, surveys and public health registries


Find Drug Side Effect reports



Fluorouracil Side Effects

Diarrhoea (463)
Nausea (335)
Dehydration (273)
Vomiting (266)
Neutropenia (243)
Febrile Neutropenia (207)
Pyrexia (187)
Mucosal Inflammation (179)
Asthenia (158)
Abdominal Pain (152)
Stomatitis (143)
Fatigue (134)
Dyspnoea (131)
Interstitial Lung Disease (117)
Decreased Appetite (116)
Pulmonary Embolism (111)
Chest Pain (110)
Anaemia (106)
Thrombocytopenia (106)
Hypotension (106)
Neutrophil Count Decreased (99)
Hypokalaemia (95)
Leukopenia (83)
Sepsis (78)
White Blood Cell Count Decreased (78)
Renal Failure Acute (75)
Pneumonia (75)
Malaise (74)
Haemoglobin Decreased (72)
Neuropathy Peripheral (69)
Pain (69)
Renal Failure (64)
Disease Progression (64)
Respiratory Failure (62)
Cardiotoxicity (62)
Dysphagia (61)
Confusional State (57)
Platelet Count Decreased (57)
Pancytopenia (55)
Fall (55)
Deep Vein Thrombosis (54)
Myocardial Infarction (53)
Arteriospasm Coronary (51)
Hyponatraemia (51)
Weight Decreased (51)
Tachycardia (48)
Chills (46)
Dizziness (46)
Septic Shock (46)
Hyperammonaemia (46)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Metastases Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Random P2 Study of Postoperative Interferon/Fluorouracil vs Low-dose Cisplatin/Fluorouracil for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.
Condition: Hepatocellular Carcinoma
Interventions: Drug: Interferon Alfa、Fluorouracil;   Drug: Cisplatin、Fluorouracil
Outcome Measures: Two-year overall survival rate;   Progression free survival time;   Overall survival time;   toxicity
2 Recruiting Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Conditions: Recurrent Rectal Cancer;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer
Interventions: Drug: trametinib;   Drug: Fluorouracil;   Radiation: radiation therapy
Outcome Measures: Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.;   Frequency of dose-limiting toxicities, assessed according to the NCI CTCAE version 4;   Local failure rate;   Progression free survival;   Overall survival;   Pathological response rate, defined as extent of tumor in the resected specimen that is classified by tumor, lymph node, metastasis (TNM) staging of the AJCC/International Union Against Cancer (UICC);   Frequency of patients undergoing sphincter preserving surgery
3 Unknown  Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pralatrexate;   Drug: Fluorouracil;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Other: high performance liquid chromatography;   Genetic: polymerase chain reaction;   Genetic: nucleic acid sequencing;   Other: pharmacological study;   Other: pharmacogenomic studies;   Genetic: polymorphism analysis
Outcome Measures: Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other week;   Clinical response to therapy in subjects with measurable disease and time to disease progression in all subjects;   Toxicity profile of the combination of PDX and 5-FU;   Pharmacokinetics of PDX and 5-FU and correlate with clinical toxicity;   Polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and correlate with clinical toxicity
4 Recruiting Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: Sorafenib;   Drug: 5-Fluorouracil (5-FU);   Radiation: Radiation
Outcome Measures: Maximum Tolerated Dose (MTD);   Number of Participants With Pathologic Response;   Number of Participants With Serious Adverse Events (SAEs)
5 Recruiting A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel plus 5-Fluorouracil;   Drug: Cisplatin plus 5-Fluorouracil;   Radiation: Radiation therapy
Outcome Measures: 1-yr overall survivals;   2-yr overall survival;   3-yr overall survival;   Disease progression-free survival;   Local progression-free survival;   Number and grade of Participants with Adverse Events
6 Recruiting Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Condition: Metastatic Gastric Cancer
Interventions: Drug: folinic acid+Fluorouracil+oxaliplatin;   Drug: Capecitabine
Outcome Measures: progression-free survival;   PFS on capecitabine maintenance;   overall survival;   number of patients with adverse events;   tolerability;   time to treatment failure;   Quality of life
7 Recruiting Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses
Conditions: Paranasal Sinus Neoplasms;   Squamous Cell Carcinoma
Interventions: Drug: Docetaxel;   Drug: 5-Fluorouracil;   Drug: Cisplatin
Outcome Measure: Number of Patients with Complete + Partial Response
8 Recruiting Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Condition: Second Line Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Glufosfamide;   Drug: Fluorouracil
Outcome Measure: Overall Survival
9 Not yet recruiting Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Conditions: Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
Interventions: Drug: imiquimod;   Drug: Fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Proportion of participants achieving complete response (Arm A and B);   Proportion of participants with spontaneous regression (Arm C);   Presence of intra-anal HSIL on cytology or histology;   Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Proportion of participants achieving complete response or spontaneous regression;   Number of quadrants with HSIL found on biopsies;   Proportion of patients achieving complete or partial responses;   Persistence of HPV type specific infections
10 Recruiting Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma
Conditions: Central Nervous System Malignancies;   Ependymoma
Intervention: Drug: 5-Fluorouracil
Outcome Measures: Estimate the maximum tolerated dose determined using the Rolling 6 design using the CTCAEv4 to assess DLT.;   Pharmacokinetic modeling of 5-Fluorouracil concentrations;   Estimate the maximum tolerated dose in less heavily pre-treated children;   Descriptive report of toxicities.;   Tumor response and progression-free survival;   Expression level of TYMS in FFPE tumor samples;   Description of association between genetic polymorphism and pharmacokinetics
11 Recruiting Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cetuximab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Radiotherapy (RT);   Other: Chemotherapy
Outcome Measure: Number of Patients with Progression-free survival (PFS)
12 Recruiting Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Conditions: Chemoradiation;   Nasopharyngeal Carcinoma
Interventions: Drug: PF (cisplatin and 5-Fluorouracil) group;   Drug: TPF (docetaxel plus cisplatin and 5-Fluorouracil) group
Outcome Measures: 3-year progress free survival(PFS);   overall survival(OS);   Adverse events;   local control rate (LCR)
13 Recruiting Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab;   Drug: everolimus;   Drug: Fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Outcome Measures: Maximum tolerated dose of everolimus in combination with sequential Fluorouracil (5-FU) and leucovorin calcium, panitumumab, modified 5-FU, leucovorin calcium, and oxaliplatin (mFOLFOX6), and mFOLFOX6 with panitumumab;   Toxicity as assessed by CTC version 3.0 at the beginning of each treatment course;   Tumor response;   Correlation of response with S6-phosphorylation and AKT-phosphorylation in archived tumor samples
14 Recruiting The Efficacy of 5-Fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Lung Metastasis
Interventions: Drug: 5-Fluorouracil;   Drug: Mitomycin
Outcome Measures: Time-to-progression(TTP)of lung metastasis;   Overall survival;   Response rates(CR + PR)of lung metastasis;   progression free survival;   Time to recurrence of intrahepatic tumor;   Disease control rates (CR + PR + SD)of lung metastasis
15 Recruiting Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: Fluorouracil;   Drug: Fluorouracil, oxaliplatin
Outcome Measures: 3-year disease free survival;   objective response rate,pathologic complete response rate, sphincter-saving surgery rate, biomarkers, quality of life, toxic profile, convenience
16 Recruiting A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Conditions: Pancreatic Cancer;   Biliary Cancer
Intervention: Drug: Gemcitabine, 5-FU and Cisplatin
Outcome Measures: Response rate;   Survival
17 Recruiting The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma
Condition: Early Stage Hepatocellular Carcinoma
Interventions: Procedure: Radical resection;   Drug: Fluorouracil Implants
Outcome Measures: To assess the clinical benefit of Fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).;   Quality of Life;   Incidence Rate of Complications;   Adverse Events
18 Recruiting Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Capecitabine
Outcome Measures: Progression-free survival;   To compare the tolerability and toxicity of orally administered eniluracil/5 FU/leucovorin regimen vs. capecitabine monotherapy
19 Recruiting PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: PD-0332991, 5-FU, oxaliplatin
Outcome Measures: Recommended Phase 2 dose and schedule;   Toxicity;   Pharmacodynamics;   Response rate;   Disease control rate;   Trough level of PD-0332991 on Day 1 of Cycles 1-4
20 Recruiting Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety
Condition: Colorectal Cancer
Interventions: Procedure: curative resection for colorectal cancer;   Drug: intra-operative 5-FU chemotherapy
Outcome Measures: disease-free survival;   safety profiles